Savara (SVRA) Return on Invested Capital (2017 - 2018)
Savara's (SVRA) quarterly Return on Invested Capital came in at 0.12% in Q4 2018, up 417.0% year-on-year from 0.02% in Q4 2017, and up 22.35% on a QoQ basis from 0.15% in Q3 2018.
Savara (SVRA) Return on Invested Capital (2017 - 2018) Analysis & Trends
Savara (SVRA) has 2 years of Return on Invested Capital data on file, last reported at 0.12% in Q4 2018.
- On a quarterly basis, Return on Invested Capital rose 417.0% year-over-year to 0.12% in Q4 2018; TTM through Dec 2018 was 0.12%, a 417.0% increase from a year earlier, with the FY2016 full-year figure at 1.81%, changed N/A from the prior year.
- Return on Invested Capital for Q4 2018 stood at 0.12%, up from 0.15% in the prior quarter.
- Over the last five years, Return on Invested Capital for SVRA reached as high as 0.12% in Q4 2018 and fell as low as 4.29% in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -0.12% |
| Sep 30, 2018 | -0.15% |
| Dec 31, 2017 | -4.29% |